Back to top

Analyst Blog

Johnson & Johnson (JNJ - Analyst Report) posted first quarter 2012 earnings (excluding special items) of $1.37 per share, a penny above the Zacks Consensus Estimate and 1.5% above the year-ago earnings of $1.35 per share.

Revenues, however, declined 0.2% year-over-year to $16.1 billion. Revenues were just shy of the Zacks Consensus Estimate of $16.3 billion. While operational factors favorably impacted sales by 1%, currency fluctuations had a negative impact of 1.2%.

Including one-time items, Johnson & Johnson reported first quarter earnings of $1.41 per share, 12.8% above the year-ago earnings of $1.25.

The Quarter in Detail

First quarter sales declined 5.1% in the domestic market. Meanwhile, international sales increased 4.1%, consisting of 6.4% operational growth and 2.3% negative currency impact. While both the Consumer and the Medical Devices & Diagnostics segments posted a decline in sales, the Pharmaceutical segment recorded a slight increase in sales.

The Medical Devices & Diagnostics segment posted sales of $6.4 billion, down 0.3% year-over year. While operational factors positively impacted Medical Devices & Diagnostics segment sales by 0.5%, foreign exchange movement negatively impacted sales by 0.8%. Sales in the domestic market increased 0.2% to $2.9 billion; international market sales declined 0.7% to $3.5 billion.

Primary contributors to growth included Biosense Webster's electrophysiology business, Diabetes Care, Vision Care, and specialty surgery. The Cardiovascular Care franchise continued to record a decline in sales reflecting the company’s exit from the drug-eluting stent market. Challenges in several Medical Devices & Diagnostics markets remain in the form of European austerity measures, pricing pressure, and a slowdown in elective surgeries which have all contributed to more tempered growth rates.

Pharmaceutical segment sales increased 1.2% year-over-year to $6.1 billion (operational growth of 2.6% and negative currency impact of 1.4%). Sales in the domestic market declined 10.8% to $3.0 billion whereas the international market grew 16.5% to $3.1 billion.

US sales were impacted by the genericization of Levaquin and supply issues regarding Doxil/Caelyx due to third-party manufacturing issues. We expect the company to provide an update on the Doxil/Caelyx situation. Johnson & Johnson will most likely find an alternative supply source.

Recently launched products like Zytiga, Stelara, Simponi and Invega Sustenna continued to perform well. Johnson & Johnson also recorded incremental sales due to the amendment of its distribution agreement with Merck (MRK - Analyst Report) for Remicade.

The Consumer segment recorded revenues of $3.6 billion in the reported quarter, down 2.4% from the first quarter of 2011. Operational factors and foreign currency movement negatively impacted sales in the segment by 0.6% and 1.8%, respectively. Sales in the domestic market declined 2.2% year-over-year to $1.3 billion, whereas the international market recorded a 2.5% year-over-year decline to $2.3 billion.

The series of OTC product recalls and the suspension of manufacturing at Fort Washington facility hampered US OTC/Nutritionals sales. First quarter 2012 OTC/Nutritionals sales declined 4.0% in the US most likely due to supply constraints on certain products. We expect product re-introductions to continue through 2012.

2012 Earnings Guidance Updated

Following the release of first quarter results, Johnson & Johnson updated its outlook for 2012. The company increased its earnings guidance by a couple of cents to $5.07 - $5.17 per share (old guidance: $5.05 to $5.15 per share). The guidance was increased to reflect the positive impact of current exchange rates. The Zacks Consensus Estimate for 2012 currently stands at $5.10 per share.

Earlier this month, Johnson & Johnson received a binding offer from Biomet, Inc. which is looking to acquire its worldwide DePuy Orthopaedics Trauma business for about $280 million.

Neutral on Johnson & Johnson

We currently have a Neutral recommendation on Johnson & Johnson, which carries a Zacks #3 Rank (short-term Hold rating). While we expect the company to continue facing headwinds in the form of pricing pressure, manufacturing issues and US healthcare reform, we believe Johnson & Johnson’s diversified business model, lack of cyclicality, and strong financial position will continue helping the company pave its way through tough situations.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%